SBFM PL4
Alternative Names: SBFM-PL4Latest Information Update: 28 Mar 2025
At a glance
- Originator Sunshine Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action SARS-CoV-2 papain-like protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Canada
- 19 Apr 2021 Sunshine Biopharma plans to submit preclinical results to the US FDA and Health Canada for authorisation to conduct a phase I trial
- 19 Apr 2021 Sunshine Biopharma plans a phase I trial for COVID-2019 infections